Drug Topics December 3, 2025
In part 3 of our interview with John C. Goodman, PhD, he discusses how TrumpRx could impact the drug supply chain—specifically PBMs.
In Donald Trump’s second term as President, he has devoted his efforts to lowering drug prices and increasing access to medications for Americans. Amid a historically complex drug supply chain consisting of prescription drug middlemen, experts believe this administration’s push to distributing drugs direct to consumers (DTC) could be a revolutionary move in decreasing drug costs.
“We, as sick people, are going to the pharmacy, getting a drug, and overpaying for drugs. Patients are paying more than they should be paying,” John C. Goodman, PhD, senior fellow at the Independent Institute and president of the Goodman Institute for...
Today's Sponsors
Today's Sponsor